US 7,405,202 B2
	CRISP polypeptides as contraceptives and inhibitors of sperm capacitation
David W. Hamilton, Edina, Minn. (US); Kenneth P. Roberts, St. Paul, Minn. (US); and Kathy M. Ensrud, Roseville, Minn. (US)
Assigned to Regents of the University of Minnesota, Minneapolis, Minn. (US)
Appl. No. 10/515,868 PCT Filed May 28, 2003, PCT No. PCT/US03/16669 § 371(c)(1), (2), (4) Date May 23, 2005, PCT Pub. No. WO03/100025, PCT Pub. Date Dec. 04, 2003.
Claims priority of provisional application 60/383628, filed on May 28, 2002.
Prior Publication US 2005/0282729 A1, Dec. 22, 2005
Int. Cl. A61K 38/00 (2006.01)

U.S. Cl. 514—12  [530/350]

3 Claims

1. A method of inhibiting sperm capacitation comprising contacting sperm that have not undergone capacitation with a cysteine-rich secretory protein (CRISP) polypeptide under capacitation conditions, wherein the CRISP polypeptide has at least 95% sequence identity to human CRISP-1 (SEQ ID NO: 1) and the CRISP polypeptide inhibits tyrosine phosphorviation of sperm proteins.